Spectris increased CSF levels of multiple HDL-like lipid transport proteins, suggesting a “coordinated biological response” ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, announced today two poster presentations at the ...
CAMBRIDGE, Mass., July 13, 2026--(BUSINESS WIRE)--Cognito Therapeutics, a clinical-stage neurotechnology company developing novel therapies for neurodegenerative disorders, today announced the ...
Image caption: Cognito Spectris investigational device. Image credit: Cognito Therapeutics Image caption: Cognito Spectris investigational device. Image credit: Cognito Therapeutics By merging ...
CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Cognito Therapeutics, a pioneer in developing disease-modifying therapeutic interventions for neurodegenerative diseases, and Aetion, a global real-world ...
Forbes contributors publish independent expert analyses and insights. I’m an analyst covering neurotech's impact on business and society. Cognito Therapeutics and West Virginia University’s ...
Cognito Therapeutics has presented new data demonstrating its Spectris neuromodulation device’s potential to slow cognitive decline and preserve white matter in patients with mild to moderate ...
In a sea of failed Alzheimer’s treatments, a digital health startup is hoping to find answers in a noninvasive treatment using light and sound. Cognito was founded by MIT Professors Li-Huei Tsai and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results